Risk stratification in early breast cancer in premenopausal and postmenopausal women: Integrating genomic assays with clinicopathological features

Current Opinion in Oncology

Volumn 31, Issue 1, 2019, Pages 29-34

  Sestak, Ivana ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Adjuvant chemotherapy; Clinicopathological parameters; Genomic assay; Prediction; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; BREAST CANCER; CANCER PROGNOSIS; CLINICAL FEATURE; DNA MICROARRAY; EARLY CANCER; GENOMICS; HUMAN; IMMUNOHISTOCHEMISTRY; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; REVIEW; BREAST TUMOR; FEMALE; GENETICS; HIGH THROUGHPUT SEQUENCING; METABOLISM; PATHOLOGY; PROCEDURES; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; POSTMENOPAUSE; PREMENOPAUSE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ESTROGEN; RISK;

EID: 85057529299     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000490     Document Type: Review

References (53)

1. Polyak K. Heterogeneity in breast cancer. J Clin Invest 2011; 121: 3786-3788.
2. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351:2817-2826.
3. Cardoso F, van't Veer LJ, Bogaerts J, et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 2016; 375:717-729.
4. Metzger Filho O, Ignatiadis M, Sotiriou C. Genomic grade index: An important tool for assessing breast cancer tumor grade and prognosis. Crit Rev Oncol Hematol 2011; 77:20-29.
5. Wallden B, Storhoff J, Nielsen T, et al. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. BMC Med Genomics 2015; 8:54.
6. Kronenwett R, Bohmann K, Prinzler J, et al. Decentral gene expression analysis: Analytical validation of the endopredict genomic multianalyte breast cancer prognosis test. BMC Cancer 2012; 12:456.
7. Sgroi DC, Sestak I, Cuzick J, et al. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: A prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol 2013; 14:1067-1076.
8. Sestak I, Cuzick J. Markers for the identification of late breast cancer recurrence. Breast Cancer Res 2015; 17:10.
9. Sestak I, Dowsett M, Zabaglo L, et al. Factors predicting late recurrence for estrogen receptor-positive breast cancer. J Natl Cancer Inst 2013; 105:1504-1511.
10. Pan H, Gray R, Braybrooke J, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 2017; 377: 1836-1846.
11. Dowsett M, Sestak I, Regan MM, et al. Integration of clinical variables for the prediction of late distant recurrence in patients with estrogen receptorpositive breast cancer treated with 5 years of endocrine therapy: CTS5.
12. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24:3726-3734.
13. Sparano JA, Gray RJ, Makower DF, et al. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 2015; 373:2005-2014.
14. Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008; 26:721-728.
15. Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: A TransATAC study. J Clin Oncol 2010; 28:1829-1834.
16. Markopoulos C, van de Velde C, Zarca D, et al. Clinical evidence supporting genomic tests in early breast cancer: Do all genomic tests provide the same information? Eur J Surg Oncol 2017; 43:909-920.
17. Albanell J, Svedman C, Gligorov J, et al. Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptorpositive, human epidermal growth factor receptor 2-negative early-stage breast cancer. Eur J Cancer 2016; 66:104-113.
18. Rouzier R, Pronzato P, Chéreau E, et al. Multigene assays and molecular markers in breast cancer: Systematic review of health economic analyses. Breast Cancer Res Treat 2013; 139:621-637.
19. Sestak I, Buus R, Cuzick J, et al. Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer: A secondary analysis of a randomized clinical trial. JAMA Oncol 2018; 545-553.
20. Cuzick J, Dowsett M, Pineda S, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol 2011; 29:4273-4278.
21. Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer.NEngl JMed 2018; 379:111-121.
22. Francis PA, Regan MM, Fleming GF, et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 2015; 372:436-446.
23. Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014; 371:107-118.
24. Stemmer SM, Steiner M, Rizel S, et al. Clinical outcomes in ER HER2 -nodepositive breast cancer patients who were treated according to the Recurrence Score results: Evidence from a large prospectively designed registry. NPJ Breast Cancer 2017; 3:32.
25. Dowsett M, Sestak I, Lopez-Knowles E, et al. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol 2013; 31:2783-2790.
26. Sestak I, Cuzick J, Dowsett M, et al. Prediction of late distant recurrence after 5 years of endocrine treatment: A combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score. J Clin Oncol 2015; 33:916-922.
27. Laenkholm AV, Jensen MB, Eriksen JO, et al. PAM50 risk of recurrence score predicts 10-year distant recurrence in a comprehensive Danish cohort of postmenopausal women allocated to 5 years of endocrine therapy for hormone receptor-positive early breast cancer. J Clin Oncol 2018; 36:735-740.
28. Gnant M, Filipits M, Greil RET-AL>. Predicting distant recurrence in receptorpositive breast cancer patients with limited clinicopathological risk: Using the PAM50 risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann Oncol 2014; 25:339-345.
29. Ohnstad HO, Borgen E, Falk RS, et al. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up. Breast Cancer Res 2017; 19:120.
30. Jensen MB, Lænkholm AV, Nielsen TO, et al. The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer. Breast Cancer Res 2018; 20:79.
31. Bartlett J, Canney P, Campbell A, et al. Selecting breast cancer patients for chemotherapy: The opening of the UKOPTIMA trial. Clin Oncol (R Coll Radiol) 2013; 25:109-116.
32. Hall PS, Smith A, Hulme C, et al. Value of information analysis of multiparameter tests for chemotherapy in early breast cancer: The OPTIMA prelim trial. Value Health 2017; 20:1311-1318.
33. Denkert C, Kronenwett R, Schlake W, et al. Decentral gene expression analysis for ER /Her2- breast cancer: Results of a proficiency testing program for the EndoPredict assay. Virchows Arch 2012; 460:251-259.
34. Buus R, Sestak I, Kronenwett R, et al. Comparison of EndoPredict and EPclin with oncotype DX recurrence score for prediction of risk of distant recurrence after endocrine therapy. J Natl Cancer Inst 2016; 108:
35. Dubsky P, et al. The EndoPredict score identifies late distant metastases in ER /HER2- breast cancer patients. Cancer Res 2012; 72(24 Supplemental): S4-S3.
36. Dubsky P, Brase JC, Jakesz R, et al. The EndoPredict score provides prognostic information on late distant metastases in ER /HER2- breast cancer patients. Br J Cancer 2013; 109:2959-2964.
37. Dubsky P, Filipits M, Jakesz R, et al. EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol 2013; 24:640-647.
38. Filipits M, Rudas M, Jakesz R, et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 2011; 17:6012-6020.
39. Martin M, Brase JC, Calvo L, et al. Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER /HER2- breast cancer patients: Results from the GEICAM 9906 trial. Breast Cancer Res 2014; 16:R38.
40. Mokbel K, Wazir U, Wazir A, et al. The impact of EndoPredict clinical score on chemotherapy recommendations in women with invasive ER( )/HER2(-) breast cancer stratified as having moderate or poor prognosis by nottingham prognostic index. Anticancer Res 2018; 38:4747-4752.
41. Fallowfield L, Matthews L, May S, et al. Enhancing decision-making about adjuvant chemotherapy in early breast cancer following EndoPredict testing. Psychooncology 2018; 27:1264-1269.
42. Ettl J, Klein E, Hapfelmeier A, et al. Decision impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker uPA/PAI-1. PLoS One 2017; 12:e0183917.
43. Jerevall PL, Ma XJ, Li H, et al. Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial. Br J Cancer 2011; 104:1762-1769.
44. Sestak I, Buus R, Cuzick JM, et al. Evaluation of the OncoMasTR prognostic signature in postmenopausal women with primary ER-positive breast cancer. J Clin Oncol 2018; 36:553; suppl; abstr 553.
45. Kinoshita T, Aogi K, TakahashiM, et al. The first report of multicenter validation study of 95-gene classifier, a multigene prognostic assay of estrogen receptor positive and node negative breast cancer patients. Ann Oncol 2017; 28:.
46. Bayani J, Yao CQ, Quintayo MA, et al. Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine. Npj Breast Cancer 2017; 3:.
47. Naoi Y, Noguchi S. Multi-gene classifiers for prediction of recurrence in breast cancer patients. Breast Cancer 2016; 23:12-18.
48. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009; 101: 1446-1452.
49. Harris LN, Ismaila N, McShane LM, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016; 34:1134-1150.
50. DuffyMJ, Harbeck N, Nap M, et al. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). Eur J Cancer 2017; 75:284-298.
51. Senkus E, Kyriakides S, Ohno S, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26(Suppl 5):v8-v30.
52. Curigliano G, Burstein HJ, P Winer E, et al. De-escalating and escalating treatments for early-stage breast cancer: The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 2017; 28:1700-1712.
53. Gyorffy B, Hatzis C, Sanft T, et al. Multigene prognostic tests in breast cancer: Past, present, future. Breast Cancer Res 2015; 17:11.